Buchumschlag

CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real‐World Setting

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Yoomi Park, Yitian Zhou, Volker M. Lauschke
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2026
Schlagworte:	Clinical Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention
von: Danwei Shao, et al.
Veröffentlicht: (2026)

Phenoconversion Due to Drug–Drug Interactions in CYP2C19 Genotyped Healthy Volunteers
von: Kenza Abouir, et al.
Veröffentlicht: (2024)

Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug‐Eluting Stent Implantation
von: Hyun Woong Park, et al.
Veröffentlicht: (2025)

Changes in S‐Citalopram Plasma Concentrations Across Pregnancy and Postpartum
von: Catherine S. Stika, et al.
Veröffentlicht: (2025)

Impact of CYP2C19 Genotype on Sertraline and Escitalopram Exposure and Antidepressant Switching Rate: A Retrospective Cohort Study of Chinese Han Patients
von: Yuhang Yan, et al.
Veröffentlicht: (2025)

CYP2C19 Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention in the Million Veteran Program
von: Catherine Chanfreau‐Coffinier, et al.
Veröffentlicht: (2025)

Repeated Intake of Grapefruit Juice Inhibits CYP2B6 , CYP2C9 , CYP2C19 , and CYP3A4 while Lingonberry Powder Does Not Induce Major CYP Enzymes in Humans
von: Laura Aurinsalo, et al.
Veröffentlicht: (2025)

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy
von: Katherine M. Robinson, et al.
Veröffentlicht: (2024)

Frequency of Key Pharmacogenes CYP2C9 , CYP2C19 , CYP2D6 , and SLCO1B1 in the Yogyakarta Population: Implications for Precision Prescribing in Indonesia
von: Dwi Aris Agung Nugrahaningsih, et al.
Veröffentlicht: (2026)

Value of Pharmacogenetic Testing Assessed with Real‐World Drug Utilization and Genotype Data
von: Kaisa Litonius, et al.
Veröffentlicht: (2024)

Use ofCYP2D6Inhibitors withCYP2D6Opioids: Association with Emergency Department Visits for Pain
von: Noor Ahmed Nahid, et al.
Veröffentlicht: (2024)

Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y12 Inhibitor Prescribing
von: Ashley N. Springer, et al.
Veröffentlicht: (2025)

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta‐Blocker Therapy
von: Julio D. Duarte, et al.
Veröffentlicht: (2024)

Association of Neurodevelopmental Disorders and Congenital Anomalies With Prenatal Multiple Sclerosis Treatment—Real‐World Historical Cohort Study
von: Bar Rosh, et al.
Veröffentlicht: (2026)

Impact of CYP2C19 Phenotype on Escitalopram Response in Geriatrics: Based on Physiologically‐Based Pharmacokinetic Modeling and Clinical Observation
von: Yoo Jin Jang, et al.
Veröffentlicht: (2024)

Physiologically Based Pharmacokinetic Modeling to Investigate the Disease‐Drug–Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID‐19 Patients with CYP2C19 Phenotypes
von: Peile Wang, et al.
Veröffentlicht: (2024)

Correction to “Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single‐Patient Data Meta‐Analysis in More Than 15,000 Individuals”
Veröffentlicht: (2024)

PharmVar GeneFocus: CYP4F2
von: Pablo Zubiaur, et al.
Veröffentlicht: (2024)

Characterization of NAT, GST, and CYP2E1 Genetic Variation in Sub‐Saharan African Populations: Implications for Treatment of Tuberculosis and Other Diseases
von: Thandeka V.B. Malinga, et al.
Veröffentlicht: (2025)

Lower Dose‐Normalized Tacrolimus Exposure in CYP3A5 *6 vs. *3 Loss‐of‐Function Allele Carriers: A Longitudinal Retrospective Real‐World Study in Kidney Transplant Recipients
von: Amar D. Levens, et al.
Veröffentlicht: (2025)

Predictive Modeling of Drug‐Related Adverse Events with Real‐World Data: A Case Study of Linezolid Hematologic Outcomes
von: Anu Patel, et al.
Veröffentlicht: (2024)

Real‐World Safety of JAK Inhibitors in Skin Immune‐Mediated Inflammatory Diseases: Boxed Warning Outcomes from a Multinational Cohort Study
von: Teng‐Li Lin, et al.
Veröffentlicht: (2026)

Ocular Complications of SGLT ‐2 Inhibitors, GLP ‐1 Receptor Agonists, and DPP ‐4 Inhibitors in T2DM Treatments: A Retrospective Real‐World Cohort Study
von: Lee‐Yuan Lin, et al.
Veröffentlicht: (2025)

Gene Polymorphisms of NLRP3 Associated With Plasma Levels of 4β‐Hydroxycholesterol, an Endogenous Marker of CYP3A Activity, in Patients With Asthma
von: Keita Hirai, et al.
Veröffentlicht: (2024)

Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy
von: Michael T. Eadon, et al.
Veröffentlicht: (2025)

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data
von: Natalia Sauer, et al.
Veröffentlicht: (2026)

Use of Real‐World Data and Real‐World Evidence in Rare Disease Drug Development: A Statistical Perspective
von: Jie Chen, et al.
Veröffentlicht: (2025)

Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay
von: Yi‐An Bi, et al.
Veröffentlicht: (2024)

CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression
von: Xiaoyu Men, et al.
Veröffentlicht: (2024)

Real‐World Outcomes of Pembrolizumab Monotherapy in Metastatic Non‐Small Cell Lung Cancer by Age and Sex: A National Population‐Based Study in Australia
von: Chin Hang Yiu, et al.
Veröffentlicht: (2026)

Solanidine Metabolites as Diet‐Derived Biomarkers of CYP2D6‐Mediated Tamoxifen Metabolism in Breast Cancer Patients
von: Samantha Medwid, et al.
Veröffentlicht: (2024)

Navigating the Real World: A Scoping Review of Structured Frameworks to Effectively Identify, Evaluate, and Select Real‐World Data Sources for Fit‐for‐Purpose Studies
von: Sonia Zebachi, et al.
Veröffentlicht: (2025)

Emulating Comparative Oncology Trials With Real‐World Evidence Studies ( ENCORE ): Process Development and Methodological Considerations for Oncology Real‐World Data
von: Janick Weberpals, et al.
Veröffentlicht: (2026)

Pharmacokinetic Evaluation of a Cinnamon Product on CYP2A6 Substrate Drugs: Application of a Novel Tool Involving the Nicotine Metabolite Ratio
von: Aiden‐Hung P. Nguyen, et al.
Veröffentlicht: (2026)

Correction to “Real‐World Outcomes of Pembrolizumab Monotherapy in Metastatic Non‐Small Cell Lung Cancer by Age and Sex: A National Population‐Based Study in Australia”
Veröffentlicht: (2026)

A Comprehensive CYP2D6 Drug–Drug–Gene Interaction Network for Application in Precision Dosing and Drug Development
von: Simeon Rüdesheim, et al.
Veröffentlicht: (2025)

Toward a More accurate, Evidence‐Based Classification of CYP Inhibitors: A Critical Appraisal of Current Systems
von: Janne T. Backman
Veröffentlicht: (2025)

The Use of Real‐World Evidence for Regulatory Decisions in China
von: Jiayue Xu, et al.
Veröffentlicht: (2024)

A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice
von: Teresa T. Ho, et al.
Veröffentlicht: (2025)

Identification of a Safe and Tolerable Carbamazepine Dosing Paradigm that Facilitates Effective Evaluation of CYP3A4 Induction
von: Amita Datta‐Mannan, et al.
Veröffentlicht: (2024)